Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
Barroso-Sousa R, Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET 3rd, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM. Barroso-Sousa R, et al. Among authors: tan wasielewski z. Clin Breast Cancer. 2020 Jun;20(3):238-245. doi: 10.1016/j.clbc.2020.01.012. Epub 2020 Jan 30. Clin Breast Cancer. 2020. PMID: 32113750 Clinical Trial.
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, Walker L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Metzger Filho O, et al. Among authors: tan wasielewski z. Ann Oncol. 2020 Sep;31(9):1231-1239. doi: 10.1016/j.annonc.2020.05.014. Epub 2020 May 24. Ann Oncol. 2020. PMID: 32461105 Free article. Clinical Trial.
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. Mayer EL, et al. Among authors: tan wasielewski z. Ann Oncol. 2020 Nov;31(11):1518-1525. doi: 10.1016/j.annonc.2020.08.2064. Epub 2020 Aug 13. Ann Oncol. 2020. PMID: 32798689 Free PMC article. Clinical Trial.
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).
Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Lee EK, et al. Among authors: tan wasielewski z. Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May. Gynecol Oncol Rep. 2020. PMID: 32083163 Free PMC article.
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF. Lee EK, et al. Among authors: tan wasielewski z. Gynecol Oncol Rep. 2019 Aug 10;29:118-122. doi: 10.1016/j.gore.2019.07.010. eCollection 2019 Aug. Gynecol Oncol Rep. 2019. PMID: 31467965 Free PMC article.